Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved expanded use of Vertex’s (NASDAQ:VRTX) lead asset ORKAMBI (lumacaftor/ivacaftor) to…
Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 10 years by 6.64% on an annualized basis producing an average annual return of 17.25%. Currently, Vertex Pharmaceuticals has a market capitalization of $72.31 billion.
Vertex Pharma’s Flagship Cystic Fibrosis Drug Scores FDA Approval For Infants
The FDA has approved Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) Orkambi (lumacaftor/ivacaftor) for expanded use to include children with cystic fibrosis (CF) ages…
Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $13,000 Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.14%. Currently, Vertex Pharmaceuticals has a market capitalization of $76.69 billion.
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) non-opioid painkiller. The company…
Where Vertex Pharmaceuticals Stands With Analysts
Vertex Pharmaceuticals (NASDAQ:VRTX) has observed the following analyst ratings within the last quarter:
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $300
HC Wainwright & Co. analyst Andrew Fein maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $275 to $300.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Piper Sandler Maintains Neutral on Vertex Pharmaceuticals, Raises Price Target to $256
Piper Sandler analyst Do Kim maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Neutral and raises the price target from $242 to $256.